Business Context and Reporting Period
Company: Absci Corp (ABSI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Absci is a clinical-stage biopharmaceutical company utilizing an AI-native "Integrated Drug Creation" platform to develop antibody-based therapeutics. The company focuses on internally developed programs and partnered drug creation agreements. As of July 31, 2026, there were 171,614,010 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Partner Program Revenue | $318 | $533 | $1,772 |
| Net Loss | $(33,210) | $(62,809) | $(56,915) |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.40) | $(0.45) |
| Operating Expenses | $34,476 | $65,537 | $60,894 |
| Cash, Cash Equivalents & Marketable Securities | $201,142 (as of June 30, 2026) | ||
| Accumulated Deficit | $(687,593) (as of June 30, 2026) |
Liquidity: The company reported a net increase in cash, cash equivalents, and restricted cash of $87.8 million for the six months ended June 30, 2026, driven primarily by financing activities.
Material Changes vs. Prior Period
- Revenue Decline: Partner program revenue decreased by 46% ($0.3 million) for the three months and 70% ($1.2 million) for the six months ended June 30, 2026, compared to the prior year periods. This is attributed to the timing of project-based milestones and the mix of ongoing program activity.
- Increased Operating Loss: Net loss increased to $62.8 million for the six months ended June 30, 2026, from $56.9 million in the prior year period. Operating expenses rose 8% year-over-year for the six-month period.
- R&D Expense Growth: Research and development expenses increased by 14% ($5.1 million) for the six months ended June 30, 2026, primarily due to increased external preclinical and clinical development costs for the lead candidate ABS-201.
- Capital Raise: In June 2026, the company completed a public offering of approximately 13.5 million shares, raising net proceeds of approximately $93.6 million. Additionally, $12.5 million was raised via an at-the-market (ATM) offering during the six-month period.
Guidance, Outlook, and Risks
Management Commentary and Pipeline
- ABS-201 (Lead Candidate): An anti-prolactin receptor antibody for pattern hair loss (PHL) and endometriosis. In June 2026, the company announced positive interim Phase 1 data from the HEADLINE trial, indicating favorable safety and an estimated half-life of at least 65 days. Full proof-of-concept data is expected in early 2027.
- Future Trials: The company anticipates initiating a Phase 2 clinical trial for ABS-201 in endometriosis in the fourth quarter of 2026.
- Capital Runway: Management believes current cash, cash equivalents, and marketable securities ($201.1 million) are sufficient to meet operating needs for at least the next 12 months.
Risks and Contingencies
- Profitability: The company has incurred significant losses since inception and expects to continue incurring losses. It has not yet demonstrated the ability to generate sufficient revenue to achieve profitability.
- Capital Needs: Additional capital will be required to fund operations and clinical development. Failure to raise capital on acceptable terms could harm the business.
- Development Uncertainty: Biologic drug development is inherently uncertain. Positive early data (e.g., from Phase 1) does not guarantee success in later-stage trials.
- Partnership Dependence: Revenue is heavily dependent on partner program milestones. Substantially all revenue for the period was attributable to foreign partners, with three partners representing 100% of revenue for the six months ended June 30, 2026.
- Regulatory and AI Risks: Risks include potential FDA delays, changes in regulatory policies, and the evolving regulatory landscape regarding the use of AI in drug discovery (e.g., EU AI Act).
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $201.1 million cash position against the reported net loss of $62.8 million for the six-month period and projected R&D spend for the ABS-201 Phase 2 trial.
- Revenue Concentration: Confirm the identity and financial stability of the three partners representing 100% of revenue, given the high concentration risk.
- ABS-201 Trial Data: Monitor the release of full proof-of-concept data expected in early 2027 and the initiation of the Phase 2 endometriosis trial in Q4 2026.
- Dilution Impact: Assess the impact of recent equity issuances (June 2026 public offering and ATM sales) on existing shareholder ownership.
- AMD Collaboration: Review the status of the strategic collaboration with Advanced Micro Devices (AMD) and the amortization of the $2.5 million premium paid for the stock issuance.